

Academia Sinica signs MoU for translational medicine development

05 September 2018 | News | By Manbeena Chawla

Following the signing of the MoU, the two sides are also looking forward to an R&D and promotion cooperation agreement within three months.



Taiwan's Academia Sinica has signed a memorandum of understanding (MoU) with government-backed Development Centre for Biotechnology (DCB) calling for collaborative efforts to accelerate the commercialization of translational medicine.

Following the signing of the MoU, the two sides are also looking forward to an R&D and promotion cooperation agreement within three months aiming to build up a cooperation model between the two parties from early research and development to product commercialization, and facilitate cooperation in order to better respond to rapidly changing market trend and technology advancements.

While focusing on the development of new drugs as well as translational medicine, the collaborative efforts will also work to integrate related services of the National Laboratory Animal Centre of the National Applied Research Laboratories (NARLabs); to coordinate the regulatory review processes at Taiwan's Food and Drug Administration (FDA); and to provide industry startups with business support from DCB's incubation centre, BioHub Taiwan.